3 completed, 3 withdrawn, 2 not yet recruiting, 2 unknown. 12 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 3, Withdrawn 3, Not yet recruiting 2, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 2 | 10 | Withdrawn 3, Completed 2, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Drug Eruptions: new trials by email Literature Review of Drug Eruptions trials Research Report on Drug Eruptions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Topical Infliximab in Autoimmune Eyes With Keratoprosthesis topical infliximab - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome | Phase 1 / Phase 2 | Withdrawn | James Chodosh, MD, MPH | 2014-11-01 | 2017-04-07 | |
| MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY BALM ARM, PLACEBO ARM - Dermatitis, Adverse Drug Reaction | Phase 1 / Phase 2 | Unknown | Basque Health Service | 86 | 2014-02-01 | 2016-08-02 |
| Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Riboflavin - Chemical Injuries, Unspecified Complication of Corneal Transplant | Phase 1 / Phase 2 | Completed | Joseph B. Ciolino, MD | 1 | 2012-03-01 | 2019-10-21 |
| Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Infliximab - Stevens-Johnson Syndrome, Corneal Blindness | Phase 1 / Phase 2 | Withdrawn | Massachusetts Eye and Ear Infirmary | 2010-12-01 | 2015-11-04 | |
| Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Terminated | Brett King | 1 | 2010-10-01 | 2016-11-30 |
| Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil sildenafil citrate - Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia | Phase 1 | Completed | Duke University | 10 | 2010-06-01 | 2012-10-30 |
| Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome Cream, 0.1% Uracil Cream - Palmar-Plantar Erythrodysesthesia, Breast Cancer | Phase 1 / Phase 2 | Completed | Nanometics (d.b.a. PHD Biosciences) | 18 | 2010-04-01 | 2019-10-08 |
Stevens-Johnson Syndrome (9) · Pemphigoid, Benign Mucous Membrane (3) · Hand-Foot Syndrome (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Breast Neoplasms (1) · Hyaline Fibromatosis Syndrome (1) · Lupus Erythematosus, Systemic (1) · Pemphigoid, Bullous (1) · Syndrome (1)
Chemically-Induced Disorders (12) · Dermatitis (12) · Drug Hypersensitivity (12) · Drug-Related Side Effects and Adverse Reactions (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Erythema (9) · Erythema Multiforme (9) · Hypersensitivity (9) · Hypersensitivity, Delayed (9) · Immune System Diseases (9) · Mouth Diseases (9) · Skin Diseases, Vesiculobullous (9) · Stomatitis (9)
Infliximab (2) · Adalimumab (1) · Clobetasol (1) · Fibroblast Growth Factor 7 (1) · Ointments (1) · Riboflavin (1) · Sildenafil Citrate (1) · Solutions (1) · daratumumab (1)
Massachusetts Eye and Ear Infirmary (2) · Assistance Publique - Hôpitaux de Paris (1) · Basque Health Service (1) · Brett King (1) · Duke University (1) · Hospices Civils de Lyon (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · James Chodosh, MD, MPH (1) · Joseph B. Ciolino, MD (1) · Nanometics (d.b.a. PHD Biosciences) (1) · University of California, Davis (1)
United States (8) · France (2) · Spain (2) · Canada (1)
James Chodosh, MD, MPH (2) · Claes H Dohlman, MD, PhD (1) · Emanual Maverakis, MD (1) · Herbert Hurwitz, MD (1) · James Cantrell, MD (1) · Joseph Ciolino, MD (1) · Mona Harissi-Dagher, MD (1) · Patricia Seaone, MD (1) · Raquel Cobos, Msc (1) · Saskia Oro, PhD (1) · Thomas Dohlman, MD (1)